Hydrea (Hydroxycarbamide)

Hydrea is a prescription tablet containing the active ingredient hydroxycarbamide. It is supplied in an oral tablet form, marketed in the European Union. Hydroxycarbamide belongs to the antimetabolite class and acts as a ribonucleotide reductase inhibitor, used as an antineoplastic and cytoreductive agent. It is classified under ATC code L01XX02 and is prescribed for several hematologic disorders. The medication is available only with a doctor's prescription.

Hydrea is indicated for the management of several blood‑related conditions where reduction of abnormal cell proliferation is required.

- Sickle cell disease to reduce the frequency of painful crises. - Chronic myelogenous leukemia (CML) as part of disease‑modifying therapy. - Polycythemia vera to control elevated red blood cell mass. - Essential thrombocythemia to lower platelet counts. - Myeloproliferative neoplasms not otherwise specified, to achieve cytoreduction. - Certain solid tumor protocols where hydroxycarbamide is used off‑label for its antiproliferative effect.

Hydrea may cause a range of adverse reactions, varying from mild to potentially serious. Patients should report any new or worsening symptoms promptly.

Common: - Nausea or vomiting, often transient and manageable with anti‑emetics. - Fatigue and generalized weakness that may affect daily activities. - Decreased white blood cell count (leukopenia), increasing infection risk. - Skin rash or discoloration, sometimes pruritic.

Serious: - Severe bone marrow suppression leading to pancytopenia, which may require transfusion. - Acute renal impairment, indicated by rising creatinine levels. - Life‑threatening allergic reactions such as anaphylaxis with airway swelling.

Before initiating Hydrea, several precautionary considerations should be reviewed to ensure safe use.

- Baseline complete blood count and renal function tests are required. - Monitor blood counts regularly during therapy to detect cytopenias early. - Use caution in patients with pre‑existing liver disease. - Avoid use during pregnancy unless benefits outweigh risks; discuss contraception. - Assess for history of hypersensitivity to hydroxycarbamide or related compounds. - Adjust dose in patients with impaired renal function. - Inform healthcare providers of any upcoming surgeries or invasive procedures.

Hydrea can interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Concurrent use with strong myelosuppressive agents (e.g., chemotherapy) that may exacerbate bone‑marrow toxicity. - Combination with nephrotoxic drugs (e.g., aminoglycosides) that increase risk of renal impairment.

Use with caution: - Anticoagulants (e.g., warfarin) as hydroxycarbamide may alter bleeding risk. - Allopurinol, which can increase hydroxycarbamide plasma levels. - Live vaccines, because immunosuppression may reduce vaccine effectiveness. - Drugs that affect hepatic metabolism (e.g., azole antifungals) may modify drug clearance. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) as they may increase gastrointestinal toxicity.